Advertisement

U.S. markets open in 18 minutes

S&P Futures
4,543.00
+6.50(+0.14%)
Dow Futures
35,585.00
+28.00(+0.08%)
Nasdaq Futures
15,380.75
+39.75(+0.26%)
Russell 2000 Futures
2,291.10
+2.30(+0.10%)
Crude Oil
85.06
+1.30(+1.55%)
Gold
1,803.60
+7.30(+0.41%)

Advertisement

WATCH NOW

Yahoo Finance's 2021 All Markets Summit — The Path Forward

Today from 9:00 a.m to 5 p.m. ET. Featuring SEC Chair Gary Gensler and other business leaders

Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

5.83-0.21 (-3.48%)

At close: 4:00PM EDT

5.83 0.00 (0.00%)
Pre-Market: 08:58AM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	6.04
Open	6.01
Bid	5.55 x 1000
Ask	6.50 x 800
Day's Range	5.79 - 6.01
52 Week Range	5.79 - 11.68
Volume	207,618
Avg. Volume	286,792

Market Cap	252.841M
Beta (5Y Monthly)	0.41
PE Ratio (TTM)	N/A
EPS (TTM)	-0.24
Earnings Date	Nov 04, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	12.67

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTSO

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Cytosorbents Corporation
BLFS: Lowering target price to $40.00BIOLIFE SOLUTIONS INC has an Investment Rating of HOLD; a target price of $40.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
Rating
Fair Value
Economic Moat
12 days agoArgus Research

All

News

Press Releases

Research Reports

PR Newswire
CytoSorbents Comments on REMOVE Study Presentation
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using CytoSorb®1 blood purification, makes additional comments on the investigator-initiated REMOVE study following the formal presentation of trial results on Saturday, October 16th at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting in Barcelona, Spain.
Simply Wall St.
Cytosorbents (NASDAQ:CTSO shareholders incur further losses as stock declines 23% this week, taking three-year losses to 44%
For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any...
PR Newswire
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb-ATR™ Antithrombotic Removal System for intraoperative